
Mechanisms of kidney protection by gliflozins There is now evidence of how SGLT2 inhibitors slow the progression of chronic kidney disease, regardless of diabetes status
SGLT2 inhibitors (gliflozins) were developed as oral antidiabetics. They enhance urinary glucose excretion by inhibiting SGLT-2 (sodium-dependent glucose co-transporter-2) in








